Spyre Therapeutics (SYRE) Total Liabilities (2015 - 2026)

Spyre Therapeutics has reported Total Liabilities for 12 years, with the latest figure at $93.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 6.85% year-over-year to $93.1 million; the trailing twelve-month figure through Mar 2026 stood at $93.1 million (up 6.85% YoY), and the FY2025 full-year result was $62.5 million, down 31.03% from the prior year.
• Total Liabilities for Q1 2026 stood at $93.1 million, up from $62.5 million in the prior quarter.
• The five-year high for Total Liabilities was $253.6 million in Q2 2023, with the low at $18.8 million in Q1 2023.
• Historically, Total Liabilities has averaged $70.8 million across 5 years, with a median of $65.6 million in 2023.
• Annual changes were most pronounced in 2023 — Total Liabilities jumped 1024.5% — and 2024, when it plunged 75.68%.
• Spyre Therapeutics' Total Liabilities stood at $20.8 million in 2022, then surged by 251.69% to $73.3 million in 2023, then grew by 23.73% to $90.7 million in 2024, then slumped by 31.03% to $62.5 million in 2025, then soared by 48.92% to $93.1 million in 2026.
• The last three Total Liabilities figures came in at $93.1 million (Q1 2026), $62.5 million (Q4 2025), and $49.5 million (Q3 2025), per Business Quant data.